BG60407B2 - Нови фармакологичноактивни съединения, методи затяхното получаване и състави, съдържащи тези съединения - Google Patents
Нови фармакологичноактивни съединения, методи затяхното получаване и състави, съдържащи тези съединения Download PDFInfo
- Publication number
- BG60407B2 BG60407B2 BG98383A BG9838394A BG60407B2 BG 60407 B2 BG60407 B2 BG 60407B2 BG 98383 A BG98383 A BG 98383A BG 9838394 A BG9838394 A BG 9838394A BG 60407 B2 BG60407 B2 BG 60407B2
- Authority
- BG
- Bulgaria
- Prior art keywords
- dihydroxy
- nitrophenyl
- formula
- compound
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
- C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
- C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C205/23—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having two nitro groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/26—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups and being further substituted by halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/34—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
- C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/43—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
- C07C45/562—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom
- C07C45/565—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom by reaction with hexamethylene-tetramine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
- C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/24—[b,e]-condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI864875A FI864875A0 (fi) | 1986-11-28 | 1986-11-28 | Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa. |
GB878712437A GB8712437D0 (en) | 1986-11-28 | 1987-05-27 | Pharmacologically active compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BG60407B2 true BG60407B2 (bg) | 1995-02-28 |
Family
ID=26158050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG98383A BG60407B2 (bg) | 1986-11-28 | 1994-01-18 | Нови фармакологичноактивни съединения, методи затяхното получаване и състави, съдържащи тези съединения |
Country Status (36)
Country | Link |
---|---|
US (1) | US4963590A (xx) |
JP (2) | JPH085781B2 (xx) |
CN (1) | CN1040062C (xx) |
AR (1) | AR243491A1 (xx) |
AT (1) | AT401053B (xx) |
AU (1) | AU621036B2 (xx) |
BE (1) | BE1003279A5 (xx) |
BG (1) | BG60407B2 (xx) |
CA (2) | CA1334967C (xx) |
CH (1) | CH685436A5 (xx) |
CS (4) | CS277018B6 (xx) |
DE (2) | DE19975025I2 (xx) |
DK (1) | DK175394B1 (xx) |
EG (1) | EG18338A (xx) |
ES (1) | ES2008359A6 (xx) |
FR (1) | FR2607493B1 (xx) |
GB (1) | GB2200109B (xx) |
GR (1) | GR871817B (xx) |
HK (1) | HK75594A (xx) |
HU (1) | HU206073B (xx) |
IE (1) | IE60320B1 (xx) |
IS (1) | IS1753B (xx) |
IT (1) | IT1225762B (xx) |
LU (1) | LU87050A1 (xx) |
LV (1) | LV10236B (xx) |
MA (1) | MA21120A1 (xx) |
MT (1) | MTP1012B (xx) |
NL (2) | NL194821C (xx) |
NO (1) | NO171450C (xx) |
NZ (1) | NZ222729A (xx) |
PH (1) | PH26145A (xx) |
PL (1) | PL152642B1 (xx) |
PT (1) | PT86236B (xx) |
RU (1) | RU2014319C1 (xx) |
SE (1) | SE503434C2 (xx) |
YU (3) | YU213587A (xx) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
GB9004348D0 (en) * | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
AU632992B2 (en) * | 1987-12-24 | 1993-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation |
MTP1031B (en) * | 1987-12-24 | 1990-10-04 | Orion Yhtymae Oy | New use of cathecol-o-methyl transferase (comt) inhibitors and their physiologically acceptable salts and esters |
US5232923A (en) * | 1988-03-18 | 1993-08-03 | Mitsui Toatsu Chemicals, Incorporated | Catechol derivatives and pharmaceutical preparations containing same |
EP0339671B1 (en) * | 1988-04-28 | 1994-08-10 | Suntory Limited | Derivative of caffeic acid and pharmaceutical composition containing the same |
GB9002337D0 (en) * | 1990-02-02 | 1990-04-04 | Orion Yhtymae Oy | Compounds useful in treating inflammatory bowel disease |
US5185370A (en) * | 1988-09-01 | 1993-02-09 | Orion-Yhtyma Oy | Substituted β-diketones and their use |
IL91382A (en) * | 1988-09-01 | 1995-06-29 | Orion Yhtymae Oy | Dicitons are converted into alkanyl or ethylmethylene, through their preparation and pharmaceutical preparations containing them |
JPH085780B2 (ja) * | 1989-04-28 | 1996-01-24 | 呉羽化学工業株式会社 | 変形性関節症治療剤 |
GB2238047B (en) * | 1989-11-03 | 1993-02-10 | Orion Yhtymae Oy | Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation |
GB9113431D0 (en) * | 1991-06-20 | 1991-08-07 | Orion Yhytma Oy | Method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde |
JPH05301838A (ja) * | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
US5656642A (en) * | 1993-04-07 | 1997-08-12 | Otsuka Pharmaceutical Co., Ltd. | Peripheral vasodilating agent containing piperidine derivative as active ingredient |
GB9419274D0 (en) * | 1994-09-23 | 1994-11-09 | Orion Yhtymae Oy | New method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde |
GB2316944B (en) * | 1995-05-24 | 1999-01-20 | Orion Yhtymae Oy | New catechol derivatives |
GB9510481D0 (en) * | 1995-05-24 | 1995-07-19 | Orion Yhtymae Oy | New catechol derivatives |
GB9626472D0 (en) | 1996-12-20 | 1997-02-05 | Aperia Anita C | New use of comt inhibitors |
FI981521A0 (fi) | 1998-07-01 | 1998-07-01 | Orion Corp | Substituoidut beta-diketonit ja niiden käyttö |
US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
FI20000635A0 (fi) * | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
US6486210B2 (en) * | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
FI20012242A0 (fi) * | 2001-11-19 | 2001-11-19 | Orion Corp | Uudet farmaseuttiset yhdisteet |
US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
US20060105036A1 (en) | 2003-05-12 | 2006-05-18 | Stephen Peroutka | Threo-dops controlled release formulation |
WO2005025561A1 (en) * | 2003-09-04 | 2005-03-24 | Synergia Pharma, Inc. | Compositions and methods for orthostatic intolerance |
EP1701936A4 (en) * | 2003-12-24 | 2007-01-24 | Wockhardt Ltd | EFFICIENT METHOD FOR PREPARING THE POLYMORPHOS FORM A FROM (E) -ENTACAPONE |
WO2005066117A1 (en) * | 2003-12-29 | 2005-07-21 | Wockhardt Limited | Stable polymorphs of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide |
WO2005063693A1 (en) * | 2003-12-29 | 2005-07-14 | Suven Life Sciences Ltd | Improved process for the preparation of entacapone |
MY142362A (en) | 2004-01-29 | 2010-11-30 | Otsuka Pharma Co Ltd | Pharmaceutical composition for promoting angiogenesis |
WO2005110462A2 (en) * | 2004-05-04 | 2005-11-24 | Children's Medical Center Corporation | Methods and compositions for treatment of preeclampsia |
WO2006040329A1 (en) * | 2004-10-12 | 2006-04-20 | Novo Nordisk A/S | 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds |
IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
AR058439A1 (es) | 2005-07-26 | 2008-02-06 | Portela & Ca Sa | Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas. |
EP1945207A2 (en) * | 2005-11-01 | 2008-07-23 | Transtech Pharma, Inc. | Pharmaceutical use of substituted amides |
JP2009514818A (ja) * | 2005-11-01 | 2009-04-09 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 置換アミドの製薬学的用途 |
DE602005017204D1 (de) * | 2005-11-09 | 2009-11-26 | Usv Ltd | Verfahren zur herstellung von hochreinem (e)-n,n-diethyl-2-cyano-3-(3,4-dihydro-5-nitrophenyl)acrylamid (entacapon) |
WO2007077572A1 (en) * | 2006-01-02 | 2007-07-12 | Actavis Group Ptc Ehf | A process for the preparation of entacapone form-a |
PL1981840T3 (pl) * | 2006-02-06 | 2012-09-28 | Orion Corp | Proces wytwarzania entakaponu |
WO2007107550A1 (en) * | 2006-03-21 | 2007-09-27 | High Point Pharmaceuticals, Llc | Adamantane derivatives for the treatment of the metabolic syndrome |
WO2007113845A1 (en) * | 2006-04-03 | 2007-10-11 | Alembic Limited | A process for the preparation of (e)-2-cyano-3-(3, 4-dihydroxy-5-nitrophenyl)-n, n-diethyl-2-propenamide (entacapone) |
BRPI0710669A2 (pt) | 2006-04-07 | 2011-08-16 | High Point Pharmaceuticals Llc | compostos ativos de dehidrogenase de 11b-hidroxiesteróide tipo 1 |
EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
EP2038255A2 (en) * | 2006-06-16 | 2009-03-25 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted piperidine carboxamides |
ATE548034T1 (de) | 2006-06-28 | 2012-03-15 | Chelsea Therapeutics Inc | Pharmazeutische zusammensetzungen mit droxidopa |
US20080004343A1 (en) * | 2006-06-29 | 2008-01-03 | Wockhardt Limited | Stable polymorphs of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide |
US8048908B2 (en) * | 2006-07-13 | 2011-11-01 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
EP1878721A1 (en) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
CA2670134A1 (en) | 2006-11-21 | 2008-08-28 | Beth Israel Deaconess Medical Center | Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications |
HUE031317T2 (hu) | 2007-01-31 | 2017-07-28 | Bial - Portela & Ca S A | Specifikus dózisprotokollal adagolt COMT inhibitor nitrokatechin származékok |
ES2319024B1 (es) | 2007-02-13 | 2009-12-11 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina. |
US8334305B2 (en) * | 2007-02-23 | 2012-12-18 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase |
JP2010519240A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、n−アダマンチルベンズアミド |
BRPI0806847A2 (pt) | 2007-02-23 | 2014-04-29 | High Point Pharmaceuticals Llc | N-adamantil benzamidas como inibidores de 11-beta-hidroxiesteróide desidrogenase |
US20110003852A1 (en) * | 2007-02-23 | 2011-01-06 | Soren Ebdrup | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
EP2134705A1 (en) * | 2007-03-09 | 2009-12-23 | High Point Pharmaceuticals, LLC | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
WO2008112562A1 (en) | 2007-03-09 | 2008-09-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
JP2010522766A (ja) * | 2007-03-28 | 2010-07-08 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11ベータ−hsd1活性化合物 |
EP1978014A1 (en) * | 2007-04-02 | 2008-10-08 | Esteve Quimica, S.A. | Process for the preparation of entacapone and intermediates thereof |
WO2008127924A1 (en) * | 2007-04-11 | 2008-10-23 | High Point Pharmaceuticals, Llc. | Novel compounds |
ES2393230T3 (es) * | 2007-04-24 | 2012-12-19 | High Point Pharmaceuticals, Llc | Uso farmacéutico de amidas sustituidas |
EP2514417A3 (en) | 2007-05-07 | 2013-01-30 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
WO2009084031A2 (en) * | 2007-12-03 | 2009-07-09 | Neuland Laboratories Ltd | An improved process for preparation of (2e)-2-cyano-3-(3,4- dihydroxy-5-nitrophenyl)n,n-diethyl-2-propenamide polymorphic form a |
EP2234608A2 (en) | 2007-12-11 | 2010-10-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
CN101965339B (zh) | 2007-12-25 | 2013-08-14 | 橘生药品工业株式会社 | 儿茶酚衍生物、含有其的药物组合物、儿茶酚衍生物的应用以及药物组合物的应用 |
EP2259777A2 (en) * | 2008-02-28 | 2010-12-15 | BIAL - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
BRPI0908731A2 (pt) | 2008-03-17 | 2017-05-16 | Bial - Portela & C A S A | formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol |
CA2729405C (en) | 2008-07-04 | 2016-08-02 | Kissei Pharmaceutical Co., Ltd. | Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition |
MX2011005037A (es) * | 2008-11-21 | 2011-06-16 | High Point Pharmaceuticals Llc | Compuestos de adamantilo benzamida. |
ES2915698T3 (es) * | 2009-04-01 | 2022-06-24 | Bial Portela & Ca Sa | Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas |
RU2701731C2 (ru) | 2009-04-01 | 2019-10-01 | Биал-Портела Энд Ка, С.А. | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения |
CN102816082B (zh) * | 2010-01-29 | 2015-03-11 | 浙江大学 | 苯甲酰胺类衍生物及制备方法和应用 |
CN101817761B (zh) * | 2010-01-29 | 2014-06-25 | 浙江大学 | 苯甲酸酯类衍生物及制备方法和应用 |
JP5778755B2 (ja) * | 2010-04-15 | 2015-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ヒドロキノンの製造方法 |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状(姿勢反射異常)の治療剤 |
CN103562379A (zh) * | 2011-05-19 | 2014-02-05 | 国立大学法人德岛大学 | 细胞分化诱导剂以及分化诱导方法 |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
ES2960805T3 (es) | 2011-12-13 | 2024-03-06 | Bial Portela & Ca Sa | Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa |
US20130197090A1 (en) | 2012-01-31 | 2013-08-01 | Chelsea Therapeutics, Inc. | Postural stability and incident functions in patients |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
JP2015519333A (ja) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物および方法 |
CA2873093A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
WO2013168023A1 (en) * | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
CN104583182A (zh) | 2012-05-23 | 2015-04-29 | 塞利克斯比奥私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
EP2852570B1 (en) | 2012-05-23 | 2020-04-22 | Cellixbio Private Limited | Composition for the treatment of inflammatory bowel disease |
CN104603097A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗多发性硬化症的组合物和方法 |
WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
TWI638802B (zh) * | 2012-05-24 | 2018-10-21 | 芬蘭商奧利安公司 | 兒茶酚o-甲基轉移酶活性抑制化合物 |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2015054302A1 (en) | 2013-10-07 | 2015-04-16 | Impax Laboratories, Inc. | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
CN104311426A (zh) * | 2014-10-27 | 2015-01-28 | 厦门大学 | 芳香硝基乙烯化合物的新用途 |
SG11201703369WA (en) | 2014-10-27 | 2017-05-30 | Cellix Bio Private Ltd | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
DK3242869T3 (da) | 2015-01-06 | 2022-01-31 | Cellix Bio Private Ltd | Sammensætninger og fremgangsmåder til behanding af inflammation og smerte |
US10532976B2 (en) * | 2015-06-23 | 2020-01-14 | National Institute Of Biological Sciences, Beijing | FTO inhibitors |
CA2993519C (en) * | 2015-06-23 | 2020-03-10 | National Institute Of Biological Sciences, Beijing | Fto inhibitors |
ES2895054T3 (es) | 2016-08-18 | 2022-02-17 | Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi | Fórmula de comprimido antiparkinson con perfil de disolución mejorado |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB902586A (en) * | 1960-01-01 | 1962-08-01 | Shell Res Ltd | Herbicidal compositions and novel compounds for use therein |
GB1188364A (en) * | 1967-05-02 | 1970-04-15 | May & Baker Ltd | Quinoline Derivatives |
BE759266A (fr) * | 1969-11-24 | 1971-05-24 | Hoffmann La Roche | Procede pour la preparation de derives de l'indole |
IE35838B1 (en) * | 1970-12-07 | 1976-06-09 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
CA1190223A (en) * | 1977-11-01 | 1985-07-09 | Anthony C. Richardson | Substrates for enzymes |
JPS5890534A (ja) * | 1981-11-25 | 1983-05-30 | Ono Pharmaceut Co Ltd | 2−アミノフエノ−ル誘導体、その製造方法およびその誘導体を有効成分として含有する治療剤 |
ES521195A0 (es) * | 1982-04-03 | 1984-06-01 | Beecham Group Plc | Un procedimiento para la preparacion de derivados de b-lactama. |
US4618627A (en) * | 1983-05-13 | 1986-10-21 | Yamanouchi Pharmaceutical Co., Ltd. | Catechol derivatives and pharmaceutical compositions thereof for inhibiting anaphylaxis (SRS-A) |
FR2557098B1 (fr) * | 1983-12-22 | 1986-06-13 | Rhone Poulenc Spec Chim | Procede de preparation de bromobenzaldehydes hydroxy et/ou alkoxy substitues |
FR2557097B1 (fr) * | 1983-12-22 | 1986-06-13 | Rhone Poulenc Spec Chim | Procede de preparation de bromobenzaldehydes hydroxy et/ou alkoxy substitues |
EP0155335A1 (de) * | 1984-03-21 | 1985-09-25 | LUDWIG HEUMANN & CO GMBH | Verfahren zur Herstellung von 3,5-Dimethoxy-4-alkoxybenzaldehyden |
DK175069B1 (da) * | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
CH676845A5 (xx) * | 1986-11-07 | 1991-03-15 | Oreal |
-
1987
- 1987-11-25 YU YU02135/87A patent/YU213587A/xx unknown
- 1987-11-26 EG EG689/87A patent/EG18338A/xx active
- 1987-11-26 MT MT1012A patent/MTP1012B/xx unknown
- 1987-11-26 CN CN87108011A patent/CN1040062C/zh not_active Expired - Lifetime
- 1987-11-27 RU SU4203731/04A patent/RU2014319C1/ru active
- 1987-11-27 PH PH36138A patent/PH26145A/en unknown
- 1987-11-27 LU LU87050A patent/LU87050A1/fr unknown
- 1987-11-27 JP JP62301388A patent/JPH085781B2/ja not_active Expired - Lifetime
- 1987-11-27 PT PT86236A patent/PT86236B/pt unknown
- 1987-11-27 SE SE8704751A patent/SE503434C2/sv not_active IP Right Cessation
- 1987-11-27 CA CA000552987A patent/CA1334967C/en not_active Expired - Lifetime
- 1987-11-27 CA CA000552986A patent/CA1289078C/en not_active Expired - Lifetime
- 1987-11-27 GR GR871817A patent/GR871817B/el unknown
- 1987-11-27 AU AU81879/87A patent/AU621036B2/en not_active Expired
- 1987-11-27 HU HU875352A patent/HU206073B/hu active Protection Beyond IP Right Term
- 1987-11-27 CS CS888440A patent/CS277018B6/cs not_active IP Right Cessation
- 1987-11-27 CH CH4633/87A patent/CH685436A5/de not_active IP Right Cessation
- 1987-11-27 FR FR878716457A patent/FR2607493B1/fr not_active Expired - Lifetime
- 1987-11-27 PL PL1987269091A patent/PL152642B1/pl unknown
- 1987-11-27 GB GB8727854A patent/GB2200109B/en not_active Expired - Lifetime
- 1987-11-27 IS IS3290A patent/IS1753B/is unknown
- 1987-11-27 US US07/126,911 patent/US4963590A/en not_active Expired - Lifetime
- 1987-11-27 BE BE8701356A patent/BE1003279A5/fr not_active IP Right Cessation
- 1987-11-27 DK DK198706230A patent/DK175394B1/da not_active IP Right Cessation
- 1987-11-27 DE DE1999175025 patent/DE19975025I2/de active Active
- 1987-11-27 CS CS888439A patent/CS276263B6/cs not_active IP Right Cessation
- 1987-11-27 AR AR87309418A patent/AR243491A1/es active
- 1987-11-27 NL NL8702857A patent/NL194821C/nl not_active IP Right Cessation
- 1987-11-27 JP JP62301387A patent/JP2735834B2/ja not_active Expired - Lifetime
- 1987-11-27 NO NO874966A patent/NO171450C/no not_active IP Right Cessation
- 1987-11-27 DE DE3740383A patent/DE3740383C2/de not_active Expired - Lifetime
- 1987-11-27 IT IT8722790A patent/IT1225762B/it active Protection Beyond IP Right Term
- 1987-11-27 ES ES8703401A patent/ES2008359A6/es not_active Expired
- 1987-11-27 AT AT0312987A patent/AT401053B/de not_active IP Right Cessation
- 1987-11-27 NZ NZ222729A patent/NZ222729A/en unknown
- 1987-11-27 MA MA21361A patent/MA21120A1/fr unknown
- 1987-11-30 IE IE324287A patent/IE60320B1/en not_active IP Right Cessation
-
1988
- 1988-12-19 CS CS888440A patent/CS844088A3/cs unknown
- 1988-12-19 CS CS888439A patent/CS843988A3/cs unknown
-
1989
- 1989-01-06 YU YU2189A patent/YU48020B/sh unknown
- 1989-01-06 YU YU2289A patent/YU47790B/sh unknown
-
1993
- 1993-06-30 LV LVP-93-805A patent/LV10236B/en unknown
-
1994
- 1994-01-18 BG BG98383A patent/BG60407B2/bg unknown
- 1994-08-04 HK HK75594A patent/HK75594A/xx not_active IP Right Cessation
-
2003
- 2003-09-26 NL NL300136C patent/NL300136I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG60407B2 (bg) | Нови фармакологичноактивни съединения, методи затяхното получаване и състави, съдържащи тези съединения | |
US5283352A (en) | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same | |
FI93350B (fi) | Menetelmä uusien farmakologisesti aktiivisten katekolijohdoksien valmistamiseksi | |
US4094992A (en) | Benzylidene derivatives | |
US4960797A (en) | N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine and the method of use thereof | |
JP2000256259A (ja) | メイラード反応阻害剤 | |
SU1156593A3 (ru) | Способ получени производных бензамида или их кислотно-аддитивных солей,или оптических изомеров | |
US20040034011A1 (en) | Derivatives of naphthalene with comt inhibiting activity | |
Sletzinger et al. | Potent decarboxylase inhibitors. Analogs of methyldopa1 | |
US3956501A (en) | N-substituted glycinates | |
EP0502110B1 (fr) | Derives d'(hetero) arylmethyloxy-4 phenyl diazole, leur procede de preparation et leur application en therapeutique | |
US4051251A (en) | Novel anti-hypertensive compositions | |
FR2594335A1 (fr) | Derives de 5-(2-piperazinoethyl)-thiazole en tant que medicaments utiles en urologie |